Compare Amphastar Pharmaceuticals Inc (AMPH) vs Stryker Corporation (SYK) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Stryker (SYK) trades at $329.78, up 0.82% on the day, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with a 63.83% gross profit margin and consistent earnings beats in recent quarters, despite a Q1 2026 miss attributed to a temporary cyber disruption. Recent news highlights the company's innovation and market position as a medtech leader.

The outlook remains positive with a consensus price target of $388.44, representing ~18% upside. Key risks include execution challenges post-cyber incident and competitive pressures, but strong cash flow and dividend growth support long-term value. Investor sentiment is buoyed by unchanged full-year guidance and healthy end-market demand.